2026 ICD-10-CM Diagnosis Code C25.4Malignant neoplasm of endocrine pancreas
ICD-10-CM Codes›C00–D49›C15-C26›C25
- Billable — Valid for Submission
- Chronic Condition
C25.4 is a billable ICD-10-CM diagnosis code for malignant neoplasm of endocrine pancreas. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 435 through 437. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Endocrine system cancers - pancreas.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Carcinoma of endocrine pancreas
- Gastrinoma
- Hyperinsulinemia due to malignant insulinoma
- Malignant gastrinoma of pancreas
- Malignant glucagonoma of pancreas
- Malignant insulinoma
- Malignant neoplasm of endocrine pancreas
- Malignant neoplasm of Islets of Langerhans
- Primary carcinoma of endocrine pancreas
- Primary carcinoma of pancreas
- Primary malignant gastrinoma of pancreas
- Primary malignant glucagonoma of pancreas
- Primary malignant insulinoma
- Primary malignant neoplasm of islets of Langerhans
- Primary malignant neuroendocrine neoplasm of pancreas
- Primary well-differentiated neuroendocrine tumor of pancreas
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Malignant neoplasm of islets of Langerhans
Use Additional Code
- code to identify any functional activity.
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Adenocarcinoma - See Also: Neoplasm, malignant, by site;
- pancreas - C25.4
- unspecified site - C25.4
- Carcinoma (malignant) - See Also: Neoplasm, by site, malignant;
- pancreas - C25.4
- unspecified site - C25.4
- pancreas - C25.4
- unspecified site - C25.4
- Tumor - See Also: Neoplasm, unspecified behavior, by site;
- pancreas - C25.4
- unspecified site - C25.4
- pancreas - C25.4
- unspecified site - C25.4
- G cell
- pancreas - C25.4
- unspecified site - C25.4
- islet cell - See: Neoplasm, benign, by site;
- malignant - See: Neoplasm, malignant, by site;
- pancreas - C25.4
- unspecified site - C25.4
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Adenocarcinoma
- islet cell
- pancreas
- Adenocarcinoma
- islet cell
- unspecified site
- Carcinoma(malignant)
- islet cell
- pancreas
- Carcinoma(malignant)
- islet cell
- unspecified site
- Gastrinoma
- malignant
- pancreas
- Gastrinoma
- malignant
- unspecified site
- Glucagonoma
- pancreas
- malignant
- Glucagonoma
- unspecified site
- malignant
- Insulinoma
- pancreas
- malignant
- Insulinoma
- unspecified site
- malignant
- Tumor
- alpha-cell
- malignant
- pancreas
- Tumor
- alpha-cell
- malignant
- unspecified site
- Tumor
- beta-cell
- malignant
- pancreas
- Tumor
- beta-cell
- malignant
- unspecified site
- Tumor
- G cell
- malignant
- pancreas
- Tumor
- G cell
- malignant
- unspecified site
- Tumor
- islet cell
- malignant
- pancreas
- Tumor
- islet cell
- malignant
- unspecified site
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Gastrinoma
a gastrin-secreting neuroendocrine tumor of the non-beta islet cells, the gastrin-secreting cells. this type of tumor is primarily located in the pancreas or the duodenum. majority of gastrinomas are malignant. they metastasize to the liver; lymph nodes; and bone but rarely elsewhere. the presence of gastrinoma is one of three requirements to be met for identification of zollinger-ellison syndrome, which sometimes occurs in families with multiple endocrine neoplasia type 1; (men 1).
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
Patient EducationClinical
Pancreatic Cancer
The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C25.4 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C25.4Overview
Is C25.4 (Malignant neoplasm of pancreas) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of endocrine pancreas on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C25.4 group to?
When malignant neoplasm of endocrine pancreas is the principal diagnosis on an inpatient stay, it groups to MS-DRG 435, 436, 437, with relative weights from 0.8533 to 1.8367 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C25.4?
Under the General Equivalence Mappings, malignant neoplasm of endocrine pancreas converts to ICD-9-CM 157.4 (mal neo islet langerhans). The mapping is a direct match.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
